The minimal important difference of the allergic rhinitis control test

Chiriac, Anca Mirela; Zhu, Rongfei; Izquierdo, Lisa; Molinari, Nicolas; Démoly, P.

doi:10.1016/j.jaip.2022.02.050

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides the ARIA severity criteria, several questionnaires -encompassing a shorter period -are used to retrospectively assess the control of AR, for example (1) the Control of Asthma and Allergic Rhinitis Test (CARAT), 10,11 evaluating symptom control during the previous 4 weeks, (2) the Allergic Rhinitis Control Test, focusing on the past 2 weeks, 12,13 and (3) the Rhinitis Control Assessment Test (RCAT), 14 with a recall period of 7 days. However, RCAT does not include questions on AR medication, and CARAT does not discriminate between asthma and AR medication or between drug classes.…”

Section: Validated a Ss E Ss Ment Of D Is E A S E Control And S E Ver...mentioning

confidence: 99%

Beyond ARIA: Will e‐diaries replace retrospective questionnaires in measuring the severity of allergic rhinitis in clinical research and daily practice?

Matricardi,

Sousa‐Pinto,

Dramburg

et al. 2023

Clin Experimental Allergy

View full text Add to dashboard Cite

Retrospective questionnaires are used since decades to assess the severity and/or control of allergic diseases. Applications on smartphones have recently facilitated the use of prospective clinical diaries, based on questionnaires filled every day by the patient. Once limited to clinical trials, these e‐diaries, based on validated disease control scores and visual analogue scales, permit a quantitative day‐by‐day measure free of recall bias. Given the advantages of this procedure, its use could be extended to the daily clinical practice. E‐diaries may facilitate (1) a more precise identification of the culprit allergen in the diagnostic work‐up of poly‐sensitized patients, (2) the stratification of patients for treatment, (3) the follow‐up of the patients under treatment for optimized shared decision‐making, and (4) a careful assessment of preventive therapies. While a few apps are being used in scientific studies, consensus on their use in daily practice should be reached and guidelines for specialists should be elaborated by scientific associations.

show abstract